论文部分内容阅读
1993年5月至1996年5月应用经皮肝动脉药物灌注栓塞(HACE)与肿瘤坏死因子联合治疗中晚期肝癌35例,与同期单独应用HACE治疗的23例作初步比较,发现联合治疗具有提高患者免疫功能、延长生存期的优点,现报告如下。 1 材料与方法 本组58例中,男46例,女12例。年龄33～68岁,中位年龄48.5岁。全部病例均经甲胎蛋白、酶学及影像学检查等证实为中晚期肝癌。其中35例进行HACE加肿瘤坏死因子联合治疗(联合治疗组)。该组在其诊断明确后即开始应用大剂量国产重组肿瘤坏死因子静注,每次剂量100万U,5次为一疗程,全部病例均进行了至少一个疗程的治疗。23例由于各种因素未能行肿瘤坏死因子治疗而单用HACE治疗(对照组)。
From May 1993 to May 1996, 35 cases of advanced hepatocellular carcinoma were treated with percutaneous transhepatic artery perfusion embolization (HACE) and tumor necrosis factor, and compared with 23 cases treated with HACE alone during the same period. It was found that combination therapy has improved. The advantages of the patient’s immune function and prolonged survival are reported below. 1 Materials and Methods In this group of 58 cases, 46 males and 12 females. Age 33 to 68 years, median age 48.5 years. All cases were confirmed by advanced alpha-fetoprotein, enzymology, and imaging studies as advanced-stage liver cancer. Thirty-five patients were treated with HACE plus tumor necrosis factor (combination therapy). The group began to apply high-dose domestic recombinant tumor necrosis factor intravenously after its diagnosis was clearly established. Each dose was 1 million U, and 5 times was a course of treatment. All cases were treated for at least one course of treatment. Twenty-three patients failed to be treated with tumor necrosis factor due to various factors and were treated with HACE alone (control group).